Ignite Creation Date:
2024-05-06 @ 4:00 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04837716
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-02-23
First Post:
2021-04-05
Brief Title:
Ensartinib Carboplatin Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-03-18
Start Date Type:
ACTUAL
Primary Completion Date:
2027-09-23
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-09-23
Completion Date Type:
ESTIMATED
First Submit Date:
2021-04-05
First Submit QC Date:
April 6 2021
Study First Post Date:
2021-04-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-21
Last Update Post Date:
2024-02-23
Last Update Post Date Type:
ACTUAL